Table 3.
Effect of PEITC compared to placebo on urinary MHBMA and DHBMA, stratified by GST genotype.
| GST genotype | Na | Geometric mean | % Difference (95% CI) | P-valueb | P-valuec interaction | |
|---|---|---|---|---|---|---|
| Placebo | PEITC | |||||
| MHBMA (ng/mg Cr)d | ||||||
| GSTT1 | ||||||
| Null | 18 | 4.4 | 6.9 | 58.7 (17.1, 115.0) | 0.004 | 0.01 |
| Present | 61 | 14.5 | 14.4 | −0.4 (−15.24, 17.1) | 0.96 | |
| GSTM1 | ||||||
| Null | 36 | 11.4 | 13.6 | 19.5 (−4.4, 49.4) | 0.12 | 0.40 |
| Present | 43 | 10.7 | 11.3 | 5.2 (−13.7, 28.2) | 0.62 | |
| GSTT1 & GSTM1 | ||||||
| Both null | 12 | 2.6 | 5.0 | 90.0 (30.3, 176.9) | 0.001 | 0.01 |
| One present | 30 | 19.3 | 19.1 | −1.3 (−21.6, 24.2) | 0.91 | |
| Both present | 37 | 11.0 | 11.3 | 2.7 (−16.4, 26.0) | 0.80 | |
| DHBMA (ng/mg Cr)d | ||||||
| GSTT1 | ||||||
| Null | 18 | 713.1 | 696.2 | −2.4 (−29.3, 34.8) | 0.88 | 0.67 |
| Present | 61 | 536.6 | 567.9 | 5.8 (−10.9, 25.7) | 0.52 | |
| GSTM1 | ||||||
| Null | 36 | 596.6 | 631.4 | 5.8 (−15.8, 32.9) | 0.63 | 0.82 |
| Present | 43 | 553.1 | 565.1 | 2.2 (−16.7, 25.3) | 0.84 | |
| GSTT1 & GSTM1 | ||||||
| Both null | 12 | 716.7 | 613.7 | −14.4 (−42.5, 27.5) | 0.45 | 0.33 |
| One present | 30 | 580.2 | 688.9 | 18.7 (−6.9, 51.5) | 0.17 | |
| Both present | 37 | 528.0 | 523.1 | −0.9 (−20.3, 23.2) | 0.93 | |
a
Value of N varies based on missing outcomes or adjusting variables.
b
Two-sided p-values were from the mixed models that test PEITC effect on the change of MHBMA and DHBMA within each specific GST genotypes before and after PEITC intake, after adjusting for creatinine-adjusted TNE.
c
Two sided p-values were from the mixed models that test the interaction term between PEITC intake and GST genotype on the levels of MHBMA and DHBMA, after adjusting for creatinine-adjusted TNE.
d
Urinary biomarkers were adjusted for creatinine and batch, and log-transformed.